Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders. All of Tranzymes product candidates have been discovered using its proprietary drug discovery (chemistry) technology, MATCH, which enables the construction of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner.
Feb 21, 2012
Tranzyme Pharma to Present at Upcoming Investor Conferences
Feb 14, 2012
Tranzyme Pharma to Report Fourth Quarter and Year-End 2011 Financial Results
Feb 27, 2012 at 4:30 PM
2012 Citi Global Healthcare Conference
Feb 29, 2012 at 8:30 AM ET
Fourth Quarter 2011 Earnings Call










